Table 4.

Anti-trichomonal activities of subfractions F_1–12.

CC Subfractions	24 hrs		48 hrs
	LC50 (µg/ml)	LC90 (µg/ml)	LC50 (µg/ml)	LC90 (µg/ml)
D7	13.81± 1.27	41.26± 8.10	12.38±4.34	37.71± 2.79†
F1	100.21± 0.83*,†	1347.09±5.14*,†	179.59 ±1.04*,†	4692.0 ± 6.19*,†
F2	26.63 ± 0.71*,†	78.43 ± 8.83*,†	23.56 ± 0.99*,†	128.14±11.24*,†
F3	22.28 ± 0.64*,†	91.00 ± 3.94*,†	24.76 ± 0.72*,†	96.63 ± 5.33*,†
F4	23.96 ± 0.70*,†	117.04 ±4.18*,†	19.46 ± 0.72*,†	99.32 ±7.26*,†
F5	21.30 ± 1.09*,†	97.23 ± 6.13*,†	21.09 ± 0.52*,†	98.49 ± 2.64*,†
F6	18.49 ± 0.89*,†	69.85 ± 5.75*,†	16.88 ± 0.35	64.71 ± 6.42*
F7	16.79 ± 0.92	60.60 ± 4.11	14.17 ± 0.95	63.59 ± 2.63*
F8	26.41 ± 0.59*,†	138.84 ± 6.68*,†	20.80 ± 0.73*,†	104.57 ± 6.26*,†
F9	47.21 ± 0.83*,†	203.96 ± 7.91*,†	42.95 ± 0.78*,†	432.16 ± 2.14*,†
F10	36.29 ± 1.02*,†	177.24 ± 7.32*,†	60.34 ± 0.70*,†	571.35 ± 5.49*,†
F11	62.13 ± 0.70*,†	382.18 ± 8.47*,†	33.00 ± 0.62*,†	198.15 ± 7.59*,†
F12	257.80 ±0.89*,†	11960.92±8.12*,†	137.74 ±1.07*,†	2114.56±5.86*,†
Metronidazole	13.67± 0.30	42.86 ± 0.87	14.04 ± 1.95	61.37 ± 8.69*

F_1–12: CC subfractions of the combined most active VLC fractions D₇ and E_2–5. N = 9; p < 0.05; *: LC₅₀ and LC₉₀ vs D₇; ^†: LC₅₀ and LC₉₀ vs metronidazole. LC₅₀ and LC₉₀: Values ± SEM.